London-based MedTech DaltonTx has exited stealth with the completion of a £4 million seed funding round to develop its adaptive, AI-enabled drug discovery platforms.

The funding will be used to build and scale the technology, which integrates directly into pharma, MedTech and CRO workflows to accelerate the development of small molecules and biologics.

The platform combines predictive modelling with reasoning engines that continuously learn from experiments, giving scientists real-time AI-enabled insights.

The seed round was led by redalpine, IQ Capital Partners and Seedcamp, with support from Oxford University Innovation.